Skip to main content

New medicines advice for NHS Wales

Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for one medicine.

  • Bevacizumab (Avastin®), given in combination with paclitaxel and cisplatin, to treat persistent, recurrent or metastatic cervical cancer in adults.

AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.

Follow AWTTC: